業績

ページタイトル画像

論文業績 2019-2024

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

2019

  1. Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y, Mishina T,Yamazaki M, Isshiki Y, Kayamori K, Kimura K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Iseki T, Nakaseko C, Sakaida E. Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. J Thromb Thrombolysis. 2019 Jul;48(1):141-148. doi: 10.1007/s11239-019-01809-w. PMID:30673940
  2. Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, Aoyama K, Saraya A, Koide S, Rizq O, Hasegawa Y, Shiraishi Y, Chiba K, Tanaka H, Nishijima D, Isshiki Y, Kayamori K, Kawajiri-Manako C, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Miyano S, Ohara O, Yokote K, Sakaida E, Kuwabara S, Sanada M, Iwama A, Ogawa S, Nakaseko C. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia. 2019 Jul;33(7):1723-1735. doi: 10.1038/s41375-018-0348-x. Epub 2019 Jan 11.
  3. Suichi T, Misawa S, Sato Y, Beppu M, Sakaida E, Sekiguchi Y, Shibuya K, Watanabe K, Amino H, Kuwabara S. Proposal of new clinical diagnostic criteria for POEMS syndrome.
    J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):133-137. doi: 10.1136/jnnp-2018-318514. Epub 2018 Oct 2. PMID: 30279213

 

  1. Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019 J83-91. doi: 10.1007/s00277-018-3492-5. [Epub 2018 Sep24]PMID:30251205

 

  1. Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T. Randomized Study of Imatinib for Chronic Myeloid Leukemia: Comparing Standard Dose Escalation with Aggressive Escalation. Blood Adv. 2019 Feb 12;3(3):312-319. doi:10.1182/bloodadvances.2018025981.PMID:30705033.

 

  1. Miki Yamazaki, Chiaki Nakaseko, Masahiro Takeuchi, Shinichi Ozawa, Yasuhiro Ishizuka, Yasuhito Hatanaka, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Shio Mitsukawa, Chikako Ohwada, Yusuke Takeda, Naoya Mimura, Tohru Iseki, Motoharu Fukazawa, Emiko Sakaida. Myeloid/lymphoid neoplasm with PDGFRB rearrangement with t(5;10)(q33;q22) harboring a novel breakpoint of the CCDC6–PDGFRB fusion gene. Internal Medicine. 2019Jul 22. doi: 10.2169/internalmedicine.3220-19. [Epub ahead of print] PMID:31327842

 

  1. Kimura K, Tsukamoto S, Takaishi K, Isshiki Y, Kayamori K, Hino Y, Ohshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Nakaseko C, Sakaida E. T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia. Leuk Lymphoma. 2019 Jun;60(6):1591-1594. doi: 10.1080/10428194.2018.1548704. Epub 2019 Jan 16. PMID: 31161870
  2. Kanayama K, Chiba T, Oshima M, Kanzaki H, Koide S, Saraya A, Miyagi S, Mimura N, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Maruyama H, Iwama A, Kato N. Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. Stem Cells Int. 2019 Apr 1;2019:9789240. doi: 10.1155/2019/9789240. eCollection 2019. PMID: 31065285

 

  1. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT). Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Leukemia. 2019 May 30. doi: 10.1038/s41375-019-0494-9. [Epub ahead of print] PMID: 31147621

 

  1. Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S. Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Ann Hematol. 2019 May 22. doi: 10.1007/s00277-019-03717-8. [Epub ahead of print] No abstract available. PMID: 31119366

 

  1. Hamanaka S, Nakagawa T, Ota S, Iida M, Ohta Y, Isshiki Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Ohwada C, Takeuchi M, Sakaida E, Arai M, Katsuno T, Nakaseko C, Nakatani Y, Kato N. Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease. Clin J Gastroenterol. 2019 Mar 22. doi: 10.1007/s12328-019-00952-4. [Epub ahead of print] PMID: 30903514

 

  1. Katsumata Y, Terada J, Abe M, Suzuki K, Ishiwata T, Ikari J, Takeda Y, Sakaida E, Tsushima K, Tatsumi K. An Analysis of the Clinical Benefit of 37 Bronchoalveolar Lavage Procedures in Patients with Hematologic Disease and Pulmonary Complications. Intern Med. 2019 Apr 15;58(8):1073-1080. doi: 10.2169/internalmedicine.1606-18. Epub 2018 Dec 18. PMID: 30568132

 

  1. Iida S, Shimazaki C, Abe M, Nakaseko C.JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma. Int J Hematol. 2019 Jun;109(6):633-640. doi: 10.1007/s12185-019-02640-y. Epub 2019 Apr 8. No abstract available. PMID: 30963472

 

  1. Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20.PMID:30127466
  2. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.

PMID: 30762219

  1. Nakamura A, Ohwada C, Takeuchi M, Takeda Y, Tsukamoto S, Mimura N, Nagisa OH, Sugita Y, Tanaka H, Wakita H, Aotsuka N, Matsue K, Yokote K, Ohara O, Nakaseko C, Sakaida E. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019 Sep 4;14(9):e0221941. doi: 10.1371/journal.pone.0221941. PMID: 31483817

 

  1. Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Rizk M, Kurosawa S, Saraya A, Kondo T, Sakaida E, Nakaseko C, Yokote K, Koseki H, Iwama A. KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. Blood Adv. 2019 Sep 10;3(17):2537-2549. doi: 10.1182/bloodadvances.2018028522. PMID: 31471323
  2. Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30627-5. doi: 10.1016/j.bbmt.2019.09.016. PMID: 31536824
  3. Tatsuzo Mishina, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yurie Nagai, Miki Yamazaki, Arata Ishii, Yutaro Hino, Yusuke Isshiki, Koji Takaishi, Kenji Kimura, Kensuke Kayamori, Shintaro Izumi, Shio Mitsukawa, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Masahiro Takeuchi, Sonoko Misawa, Tohru Iseki, Satoshi Kuwabara, Chiaki Nakaseko, Emiko Sakaida. Successful autologous stem cell transplantation for POEMS syndrome with an unusually large osteolytic lesion: A case report and literature review. International Journal of Myeloma in press
  4. Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).　Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplant. 2019 Sep 19. doi: 10.1038/s41409-019-0689-8. [Epub ahead of print]
  5. Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. Bone Marrow Transplant. 2019 Dec;54(12):2020-2026. doi: 10.1038/s41409-019-0585-2. Epub 2019 Jun 11.PMID: 31186516
  6. Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7.　PMID: 31701481
  7. Masahiro Sakaguchi, Hiroki Yamaguchi, Marika Kuboyama, Yuho Najima, Kensuke Usuki, Toshimitsu Ueki, Iekuni Oh, Shinichiro Mori, Eri Kawata, Nobuhiko Uoshima, Yutaka Kobayashi, Shinichi Kako, Kenji Tajika, Katsuhiro Shono, Kensuke Kayamori, Masao Hagihara, Junya Kanda, Hitoji Uchiyama, Junya Kuroda, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Saiko Kurosawa, Kenta Date, Nana Nakajima, Atsushi Marumo, Ikuko Omori, Yusuke Fujiwara, Kazuki Terada, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Yoshinobu Kanda, Kazuteru Ohashi, Takahiro Fukuda, Koiti Inokuchi. Significance of FLT3‐tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z.
  8. Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT).　 Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25693. [Epub ahead of print]　PMID: 31804748
  9. Rizk M, Rizq O, Oshima M, Nakajima-Takagi Y, Koide S, Saraya A, Isshiki Y, Chiba T, Yamazaki S, Ma A, Jin J, Iwama A, Mimura N. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.　 Cancer Sci. 2019 Dec;110(12):3695-3707. doi: 10.1111/cas.14207. Epub 2019 Oct 22.　PMID: 31571328

 

 

和文論文

2019

  1. 三村尚也. 骨髄腫モデルマウスによる病態の解明と新規治療の開発. 月刊「血液内科」　特集・多発性骨髄腫の分子病態解明の進歩と新たな治療展開. 第78巻第1号p13-17　2019年1月
  2. 栢森健介, 堺田惠美子.  腎と透析 2019年 増刊号　全身疾患と腎update　第5章　9. 白血病  テーマ：白血病　血液専門医の視点より in press
  3. 日野裕太郎, 堺田惠美子.　 月刊　血液内科　特集／慢性骨髄性白血病（CML）診療の最近の進歩 チロシンキナーゼ阻害薬による有害事象とその対策  2019 in press
  4. 三村　尚也、井関　徹. 形質細胞性疾患における脾臓病変. 特集・脾臓研究の進歩と臨床.  月刊「血液内科」　第78巻6号p817-820（2019年6月）
  5. 立花 美智子, 塚本 祥吉, 三川 紫緒, 竹田 勇輔, 大和田 千桂子, 大島 渚, 武内 正博, 三村 尚也, 井関 徹, 中世古 知昭, 堺田 惠美子. HCTC主導骨髄バンクコーディネートシステムによるコーディネート期間の短縮. 日本造血細胞移植学会雑誌. 2019 年 8 巻 2 号 p. 84-89
  6. 大島渚、堺田惠美子、横手幸太郎　加齢に伴うクローン性造血とアテローム性動脈硬化型心血管障害リスク　『Cardio-Renal Diabetes』 Vol. 8, No. 3., in press
  7. 石井改、堺田惠美子. 急性リンパ性白血病（ALL）.ALLに対する造血細胞移植. 『白血病マニュアル　改訂第4版』in press
  8. 三村尚也.　プロテアソーム阻害剤による心毒性の発症機構. 月刊「血液内科」79巻5号p635-638（2019年11月）
  9. 三村尚也、堺田惠美子、中世古知昭. POEMS症候群の形質細胞における遺伝子異常.月刊「腫瘍内科」24巻6号p691-696（2019年12月）
  10. 山崎美貴、塚本祥吉、中世古知昭. 自家移植後の多発性骨髄腫患者に対するイクサゾミブ維持療法. 月刊「血液内科」 in press
  11. 中世古知昭　[POEMS syndrome: advances in molecular pathophysiology and treatment]. Rinsho Ketsueki. 2019;60(8):979-987. doi: 10.11406/rinketsu.60.979. Japanese.PMID: 31484899